Circulating spike theory

From Long Haul Wiki
Jump to navigation Jump to search

The Simoa assay is a highly sensitive test which uses an antibody (attached to a magnetic bead) to detect low quantities of a target antigen. However, validation studies of the assay reveal the limitations of this antibody-dependent test as antibodies are known to attach themselves to antigens that are slightly off-target. A paper by David Walt (Simoa inventor) and his co-authors (Ogata et al.) detected "spike" in pre-pandemic samples. See Figure S6 in the supplementary data. As these test results are clearly false positives (the spike protein did not exist pre-pandemic), the authors proposed combining the results of both the S1 and N antigen tests to improve the sensitivity and specificity of the test. Looking for both a positive S1 and N result reduces the impact of the occasional false positive on either test.

A later June 2022 paper with many of the same authors (Swank et al.) dropped the original methodology and introduced a new one. The Simoa assay generally detected full-length Spike antigens but not S1 or N. The authors claimed that they detected full-length spike in the blood of Long COVID patients based on this new methodology. Both the earlier and later paper discuss how full-length spike protein is often cleaved to create a S1 subunit; the newer paper provides a discussion as to why full-length spike protein is not being cleaved as expected.

A Jan 2023 paper on vaccine-induced myocarditis patients (Yonker et al.) also features Simoa-related authors as co-authors. This paper claims to have found full-length spike, mirroring the claims of the June 2022 paper which 'found' full-length spike in PASC patients.